697,552 Shares in Surgery Partners, Inc. $SGRY Acquired by Man Group plc

Man Group plc bought a new stake in Surgery Partners, Inc. (NASDAQ:SGRY) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 697,552 shares of the company’s stock, valued at approximately $11,719,000.

Several other hedge funds have also bought and sold shares of SGRY. Jupiter Topco LLC purchased a new position in Surgery Partners in the 2nd quarter worth approximately $233,220,000. Janus Henderson Group PLC raised its position in shares of Surgery Partners by 3.8% during the 4th quarter. Janus Henderson Group PLC now owns 13,537,984 shares of the company’s stock valued at $209,162,000 after buying an additional 501,401 shares in the last quarter. Pentwater Capital Management LP lifted its holdings in shares of Surgery Partners by 66.9% during the 3rd quarter. Pentwater Capital Management LP now owns 11,681,000 shares of the company’s stock worth $252,777,000 after acquiring an additional 4,681,000 shares during the last quarter. UBS Group AG lifted its holdings in shares of Surgery Partners by 111.4% during the 4th quarter. UBS Group AG now owns 7,803,974 shares of the company’s stock worth $120,571,000 after acquiring an additional 4,113,052 shares during the last quarter. Finally, BlackRock Inc. purchased a new position in Surgery Partners in the second quarter worth $104,857,000.

Insider Buying and Selling at Surgery Partners

In other news, Director Teresa Deluca bought 10,000 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were purchased at an average price of $14.35 per share, for a total transaction of $143,500.00. Following the completion of the acquisition, the director owned 66,843 shares of the company’s stock, valued at approximately $959,197.05. This trade represents a 17.59% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 2.00% of the company’s stock.

Surgery Partners Trading Down 0.8%

NASDAQ SGRY opened at $13.93 on Friday. The firm has a market cap of $1.82 billion, a PE ratio of -19.90, a price-to-earnings-growth ratio of 4.33 and a beta of 1.91. Surgery Partners, Inc. has a 1-year low of $11.41 and a 1-year high of $23.44. The stock has a 50-day moving average of $15.51 and a 200-day moving average of $14.39. The company has a current ratio of 1.95, a quick ratio of 1.78 and a debt-to-equity ratio of 1.18.

Surgery Partners (NASDAQ:SGRY) last posted its quarterly earnings results on Monday, August 10th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.04. The business had revenue of $848.90 million for the quarter, compared to analyst estimates of $830.03 million. Surgery Partners had a positive return on equity of 0.88% and a negative net margin of 2.63%.Surgery Partners’s revenue for the quarter was up 2.7% compared to the same quarter last year. During the same period last year, the company earned $0.17 EPS. As a group, sell-side analysts forecast that Surgery Partners, Inc. will post 0.22 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Raymond James Financial set a $18.00 target price on Surgery Partners in a research note on Tuesday, August 11th. Jefferies Financial Group reiterated a “buy” rating and issued a $17.00 price objective on shares of Surgery Partners in a report on Wednesday, May 6th. Zacks Research lowered Surgery Partners from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 10th. Cantor Fitzgerald reissued an “overweight” rating and set a $18.00 price objective on shares of Surgery Partners in a report on Tuesday, August 11th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Surgery Partners in a research note on Friday, August 21st. Seven research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $19.45.

Surgery Partners Profile

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.